Proteolysis-targeting chimeras (PROTACs) are heterobifunctional small molecules that exploit the ubiquitin-proteasome system to drive catalytic, sub-stoichiometric degradation of target proteins. This degradation-based mechanism provides a mechanistic advantage compared with occupancy-driven inhibitors and enables targeting of proteins previously considered 'undruggable.' However, multiple delivery and pharmacokinetic limitations impede the clinical translation of PROTACs.
Exosomes are nanoscale extracellular vesicles produced by cells that possess innate biocompatibility, low immunogenicity, and favorable circulation properties. Their natural ability to carry and transfer molecular cargo, and to cross biological barriers such as the blood-brain barrier, makes them an attractive, biologically integrated platform to address specific shortcomings of conventional PROTAC formulations.
The primary constraints for delivering PROTACs described in the source include:
These factors collectively restrict pharmacokinetic profiles, therapeutic windows, and practical clinical use when PROTACs are administered without specialized delivery systems.
The review highlights several attributes of exosomes that may mitigate PROTAC delivery problems:
These properties support the rationale for encapsulating PROTACs within exosomes to enhance stability, biodistribution, and tissue targeting while potentially reducing systemic exposure and off-target effects.
The review describes a spectrum of strategies for deploying exosomes as delivery platforms for PROTACs. Key considerations include:
Collectively, these engineering approaches aim to tailor exosome preparations to the pharmacological and pharmacodynamic needs of specific PROTACs and disease contexts.
Exosomal encapsulation can influence multiple mechanistic steps relevant to PROTAC function:
The review synthesizes these mechanistic rationales to support exosomes as a delivery modality capable of addressing several delivery-limited aspects of PROTAC pharmacology.
The authors map exosome-mediated PROTAC delivery to several therapeutic domains where targeted protein degradation could be impactful:
The review positions exosome-mediated delivery as a potential platform to broaden the clinical utility of PROTACs across these varied indications.
The abstract cites proof-of-concept evidence showing enhanced outcomes with exosome-encapsulated PROTACs. One example detailed in the review abstract is the use of camel milk-derived exosomes to deliver the BRD4-targeting PROTAC ARV-825. Reported benefits in that example included improved permeability, lower IC50 values, and enhanced oral bioavailability compared with the PROTAC delivered without exosomal encapsulation.
The abstract does not enumerate additional experimental parameters, dosing regimens, or clinical outcomes; such details would be found in the full text and underlying studies referenced by the review.
Despite the promising rationale and initial proof-of-concept reports, the review identifies critical obstacles that must be overcome before exosome-mediated PROTAC therapies reach clinical practice. Principal challenges include:
The authors outline these translational bottlenecks and suggest that addressing manufacturing, purification, and standardization gaps will be essential next steps. The abstract indicates future directions focus on refining loading and targeting strategies, improving scalable processes, and advancing preclinical and clinical evaluation, but specific timelines or detailed development plans were not reported in the abstract.
Overall, the review synthesizes the rationale, engineering approaches, early experimental evidence, and outstanding translational hurdles for exosome-mediated targeted protein degradation using PROTACs, suggesting this combined platform could expand therapeutic reach across cancer, infectious, neurodegenerative, and inflammatory diseases.